<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01587378</url>
  </required_header>
  <id_info>
    <org_study_id>2011/1434</org_study_id>
    <secondary_id>2011-002203-15</secondary_id>
    <nct_id>NCT01587378</nct_id>
  </id_info>
  <brief_title>Metformin to Prevent Late Miscarriage and Preterm Delivery in Women With Polycystic Ovary Syndrome</brief_title>
  <acronym>PregMet2</acronym>
  <official_title>A Prospective, Randomized, Double-blind, Multi-centre Study, Where the Possible Effect of Metformin to Prevent Late Miscarriage and Preterm Delivery is Studied in Women With Polycystic Ovary Syndrome (PCOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Landspitali University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sykehuset Telemark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alesund Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital of Vestfold</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordlandssykehuset HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norrlands universitetssjukhus Umeå</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sykehuset Innlandet HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vestre Viken Ringerike Sykehus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of the PregMet 2 Study is to investigate whether metformin prevents late
      miscarriages and preterm deliveries in PCOS women treated with metformin from first trimester
      of pregnancy to delivery in a large, randomized, controlled, multi-centre trial setting.

      The investigators hypothesis is that metformin compared to placebo treatment from the first
      trimester to term, reduces the prevalence of late miscarriage (gestational week 13-22) and
      preterm birth (gestational week &lt; 37) in PCOS women diagnosed according to Rotterdam 2003
      consensus criteria, with singleton pregnancy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2012</start_date>
  <completion_date type="Actual">October 1, 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>combined incidence of late miscarriages and preterm births</measure>
    <time_frame>at delivery</time_frame>
    <description>This includes spontaneous births, induced vaginal deliveries and operative deliveries on medical indications.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NICU admissions and total number of days in NICU/baby</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients hospitalized</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of hospitalization days/ hospitalized participant</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of gestational diabetes</measure>
    <time_frame>up to delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of preeclampsia</measure>
    <time_frame>up to delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SNP</measure>
    <time_frame>at delivery</time_frame>
    <description>SNP analysis (genetic analysis)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">489</enrollment>
  <condition>Pregnancy</condition>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 500 mg tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery</description>
    <arm_group_label>metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>identical placebo tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-45 years

          -  PCOS diagnosed or reconfirmed according to Rotterdam 2003 criteria, not more than 5
             years prior to inclusion

          -  Mode of conception: Any

          -  Single, viable fetus, diagnosed by vaginal ultrasound

          -  Gestational week at inclusion: week 6 + 0 to 12 + 0

          -  Wash out for metformin: at least 7 days

          -  Able to communicate fluently in the official language at the study cite or English

        Exclusion Criteria:

          -  Any type of diabetes (except GDM in former pregnancy)

          -  Known liver disease or ALAT &gt; 100 IU/L

          -  Known kidney disease or creatinine &gt; 110 μmol/L

          -  Known alcohol or drug abuse

          -  Use of drugs interfering with metformin: erytromycin (or other macrolides),
             cimetidine, anticoagulation therapy

          -  Unsuitable for participation of other reasons
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eszter I Vanky, md phd</last_name>
    <role>Study Director</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landspital University Hospital</name>
      <address>
        <city>Reykjavik</city>
        <zip>101</zip>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5000</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nordlandssykehuset HF</name>
      <address>
        <city>Bodø</city>
        <zip>1480</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sykehuset Innlandet</name>
      <address>
        <city>Brumunddal</city>
        <zip>2380</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vestre Viken Hospital Trust</name>
      <address>
        <city>Drammen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vestre Viken Ringerike sykehus</name>
      <address>
        <city>Honefoss</city>
        <zip>3511</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sykehuset Telemark</name>
      <address>
        <city>Skien</city>
        <zip>3710</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentralsykehuset i Vestfold</name>
      <address>
        <city>Tønsberg</city>
        <zip>3116</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sykehuset Ålesund</name>
      <address>
        <city>Ålesund</city>
        <zip>6026</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhus</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norrlands universitetssjukhus</name>
      <address>
        <city>Umeå</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iceland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2012</study_first_submitted>
  <study_first_submitted_qc>April 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2012</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>miscarriage</keyword>
  <keyword>preterm birth</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

